DAIICHI SANKYO CO., LTD. TSE:4568
Reference Data
(Consolidated Financial Results for Q1 FY2021)
July 30, 2021
Daiichi Sankyo Co., Ltd.
https://www.daiichisankyo.com
Contents
1. | Consolidated Statement of Profit or Loss | P1 |
2. | Sheet to adjust Operating Profit to Core Operating Profit | P2 |
3. | Revenue of Global Products | P3 |
4. | Revenue by Business Units and Products | P4 |
5. | Consolidated Statement of Financial Position | P7 |
6. | Consolidated Statement of Cash Flows | P9 |
7. | Number of Employees | P10 |
8. | Capital Expenditure, Depreciation and Amortization | P10 |
9. | Summary of Product Outlines | P11 |
10. | Quarterly Data | P12 |
11. | Historical Data | P17 |
12. | Major R&D Pipeline (Innovative pharmaceuticals) | P21 |
1. Consolidated Statement of Profit or Loss
JPY Bn
Revenue
Cost of sales※1
Gross Profit
SG&A expenses※1
R&D expenses※1
Core Operating Profit
Other income※2
Other expenses※2
Operating Profit
Financial income/expenses
Share of profit or loss of investments accounted for using the equity method
Profit before tax
Income taxes
FY2020 Q1 | FY2021 Q1 | |||||||
to revenue | Results | to revenue | Results | (vs. Forecast (%)) | YoY | YoY (%) | ||
100.0% | 236.9 | 100.0% | 264.1 | 26.7% | 27.1 | +11.4% | ||
34.7% | 82.2 | 32.2% | 85.2 | 26.6% | 2.9 | +3.6% | ||
65.3% | 154.7 | 67.8% | 178.9 | 26.7% | 24.2 | +15.6% | ||
30.3% | 71.8 | 30.8% | 81.2 | 24.3% | 9.4 | +13.1% | ||
20.6% | 48.9 | 20.5% | 54.0 | 20.3% | 5.2 | +10.5% | ||
14.4% | 34.1 | 16.5% | 43.7 | 62.4% | 9.6 | +28.2% | ||
0.1 | 2.1 | 2.0 | ||||||
0.0 | 0.0 | -0.0 | ||||||
14.4% | 34.1 | 17.3% | 45.8 | 65.4% | 11.6 | +34.1% | ||
7.2 | 1.3 | -6.0 | ||||||
0.0 | -0.0 | -0.0 | ||||||
17.5% | 41.4 | 17.8% | 47.1 | 67.2% | 5.7 | +13.7% | ||
9.6 | 11.8 | 2.3 |
Forex impact: +6.6
(USD: +0.9, EUR: +3.5, ASCA: +2.2)
Forex impact: +0.1
(USD: +0.4, EUR: -0.7, ASCA: +0.4)
Forex impact: +2.3
(USD: +0.4, EUR: +1.2, ASCA: +0.7)
Forex impact: +1.2
(USD: +0.4, EUR: +0.8, ASCA: +0.1)
Forex impact: +3.0
(USD: -0.2, EUR: +2.2, ASCA: +1.1)
- Recognition of financial income due to decrease in contingent consideration of quizartinib acquisition -4.7 (FY2020)
- Deterioration in forex gains/losses -0.6
FY2021
to revenue | Forecast | YoY | YoY (%) | |
100.0% | 990.0 | 27.5 | +2.9% | |
32.3% | 320.0 | -17.8 | -5.3% | |
67.7% | 670.0 | 45.2 | +7.2% | |
33.7% | 334.0 | 15.5 | +4.9% | |
26.9% | 266.0 | 38.6 | +17.0% | |
7.1% | 70.0 | -8.9 | -11.2% | |
- | -0.6 | |||
- | -15.6 | |||
7.1% | 70.0 | 6.2 | +9.7% |
7.1% 70.0 -4.1 -5.6%
Profit for the year | 13.4% | 31.8 | 13.3% | 35.2 | 70.4% | 3.4 +10.7% | 5.1% | 50.0 | -25.8 | -34.1% | |||||||
Profit attributable to owners of the Compan | y | 13.4% | 31.9 | 13.3% | 35.2 | 70.4% | 3.4 +10.6% | 5.1% | 50.0 | -26.0 | -34.2% | ||||||
Tax rate | 23.1% | 25.2% | |||||||||||||||
Overseas sales ratio | 38.6% | 44.7% | |||||||||||||||
Currency Rate (Average) | Currency Rate (Average) | ||||||||||||||||
USD/JPY | 107.62 | 109.49 | 105.00 | ||||||||||||||
EUR/JPY | 118.47 | 131.95 | 120.00 | ||||||||||||||
Annual impact of one yen change | |||||||||||||||||
Forecast | |||||||||||||||||
USD | EUR | ||||||||||||||||
*This report is not subject to audit procedures. | Revenue | 1.8 JPY Bn | 0.9 JPY Bn | ||||||||||||||
Operating Profit | -0.6 JPY Bn | 0.3 JPY Bn | |||||||||||||||
※1 Temporary gains and losses are excluded for cost of sales, SG&A expenses and R&D expenses
※2 See page 2 for the definition of temporary gains and losses and the adjustment of operating profit and core operating profit
1
2. Sheet to adjust Operating Profit to Core Operating Profit
FY2020 Q1 Results
Operating | Adjustment | Operating | ||||||||
JPY Bn | gains and losses | gains and losses | gains and losses | gains and losses related to loss | ||||||
Profit (full) | related to sale of fixed | Others | Profit (Core) | |||||||
related to restructuring | related to impairment, | compensation, reconciliation | ||||||||
assets | ||||||||||
Revenue | 236.9 | 236.9 | ||||||||
Cost of sales | 82.2 | - | - | - | - | - | 82.2 | |||
SG&A expenses | 71.8 | -0.0 | - | 0.0 | - | - | 71.8 | |||
R&D expenses | 48.8 | -0.1 | - | - | - | - | 48.9 | |||
Core Operating Profit | 34.1 | -0.1 | - | 0.0 | - | - | 34.1 | ＜Major Other income and Other expenses＞ | ||
Other income | 0.1 | - | - | - | - | 0.1 | ||||
(Cost of sales) | - | |||||||||
(SG&A expenses) | 0.0 | 0.0 | ||||||||
(R&D expenses) | 0.1 | 0.1 | ||||||||
Other expenses | 0.0 | - | 0.0 | - | - | 0.0 | ||||
(Cost of sales) | - | |||||||||
(SG&A expenses) | 0.0 | 0.0 | 0.0 | |||||||
(R&D expenses) | - | |||||||||
Operating Profit (full) | 34.1 | - | - | - | - | - | 34.1 |
FY2021 Q1 Results
Operating | Adjustment | Operating | |||||||||
gains and losses | gains and losses | gains and losses | gains and losses related to loss | ||||||||
JPY Bn | Profit (full) | related to sale of fixed | Others | Profit (Core) | |||||||
related to restructuring | related to impairment, | compensation, reconciliation | |||||||||
assets | |||||||||||
Revenue | 264.1 | 264.1 | |||||||||
Cost of sales | 85.2 | -0.0 | - | - | - | - | 85.2 | ||||
SG&A expenses | 79.1 | -2.1 | - | - | - | -0.0 | 81.2 | ||||
R&D expenses | 54.0 | -0.0 | - | - | - | - | 54.0 | ||||
Core Operating Profit | 45.8 | -2.1 | - | - | - | -0.0 | 43.7 | ＜Major Other income and Other expenses＞ | |||
Other income | 2.1 | - | - | - | 0.0 | 2.1 | *1 Gains related to sale of Osaka logistics | ||||
(Cost of sales) | 0.0 | 0.0 | |||||||||
(SG&A expenses) | 2.1 | *1 | 0.0 | 2.1 | |||||||
(R&D expenses) | 0.0 | 0.0 | |||||||||
Other expenses | 0.0 | - | - | - | - | 0.0 | |||||
(Cost of sales) | - | ||||||||||
(SG&A expenses) | 0.0 | 0.0 | |||||||||
(R&D expenses) | - | ||||||||||
Operating Profit (full) | 45.8 | - | - | - | - | - | 45.8 |
As an indicator of ordinary profitability, "core operating profit" which excludes temporary gains and losses (other revenue and other expenses) from operating income is disclosed. Gains and losses related to: sale of fixed assets, restructuring (excluding the sales of pipeline and launched products), impairment, loss compensation, reconciliation, and other non-temporary and material gains and losses are included in the "temporary gains and losses".
2
3. Revenue of Global Products | FY2020 Q1 | FY2021 Q1 | FY2021 | ||||||||||||||
Results | Results | (vs. Forecast (%)) | YoY | YoY (%) | Forecast | Forecast | vs. Forecast | YoY | YoY (%) | ||||||||
JPY Bn | (as of Apr.) | (as of Jul.) | (as of Apr.) | ||||||||||||||
Trastuzumab deruxtecan | anti-cancer agent | 7.9 | 16.0 | (21.8%) | 8.1 | +102.2% | 84.0 | 73.1 | -11.0 | 29.6 | +68.1% | ||||||
(HER2-directed antibody drug conjugate) | |||||||||||||||||
Product sales | 5.2 | 13.0 | (21.2%) | 7.7 | +148.5% | 69.4 | 61.0 | -8.4 | 30.9 | +102.8% | |||||||
Enhertu (JPN) | 0.2 | 2.2 | (16.2%) | 2.0 | +905.0% | 13.4 | 13.4 | - | 9.0 | +206.9% | |||||||
Enhertu (US) | 5.0 | 9.6 | (22.6%) | 4.6 | +91.8% | 50.4 | 42.4 | -8.0 | 16.7 | +65.0% | |||||||
Enhertu (EU) | - | 1.2 | (23.6%) | 1.2 | - | 5.4 | 5.1 | -0.4 | 5.0 | - | |||||||
Enhertu (ASCA: Asia, South and Central America) | - | - | - | - | - | 0.2 | 0.2 | - | 0.2 | - | |||||||
Upfront payment | 2.5 | 2.5 | (25.0%) | - | - | 9.8 | 9.8 | - | - | - | |||||||
Regulatory milestone payment | 0.2 | 0.6 | (25.0%) | 0.3 | +146.0% | 4.8 | 2.2 | -2.6 | -1.3 | -37.2% | |||||||
US HER2+ Breast Cancer 3L | 0.2 | 0.2 | (25.0%) | - | - | 0.9 | 0.9 | - | - | - | |||||||
EU HER2+ Breast Cancer 3L | - | 0.1 | (25.0%) | 0.1 | - | 0.5 | 0.5 | - | -0.5 | -50.0% | |||||||
US HER2+ Gastric Cancer 2L+3L | - | 0.2 | (25.0%) | 0.2 | - | 0.8 | 0.8 | - | -0.8 | -50.0% | |||||||
US HER2+ or HER2 Mutant NSCLC 2L | - | - | - | - | - | 2.6 | - | -2.6 | - | - | |||||||
Datopotamab deruxtecan | anti-cancer agent | - | 1.5 | (25.0%) | 1.5 | - | 5.8 | 5.8 | - | 1.9 | +47.0% | ||||||
(TROP2-directed antibody drug conjugate) | |||||||||||||||||
Upfront payment | - | 1.5 | (25.0%) | 1.5 | - | 5.8 | 5.8 | - | 1.9 | +47.0% | |||||||
Edoxaban | anticoagulant | 38.7 | 49.5 | (25.5%) | 10.8 | +27.8% | 188.4 | 194.0 | 5.6 | 28.1 | +16.9% | ||||||
Lixiana (JPN) | 19.8 | 22.9 | (24.8%) | 3.1 | +15.5% | 90.4 | 92.1 | 1.7 | 14.7 | +19.0% | |||||||
Savaysa (US) | 0.6 | 0.5 | (25.2%) | -0.1 | -9.4% | 2.2 | 2.0 | -0.2 | -1.0 | -32.0% | |||||||
Lixiana (EU) | 16.4 | 23.4 | (26.1%) | 7.0 | +42.4% | 84.6 | 89.7 | 5.0 | 13.0 | +16.9% | |||||||
Edoxaban (ASCA: Asia, South and Central America) | 1.9 | 2.7 | (26.9%) | 0.8 | +41.1% | 11.1 | 10.2 | -1.0 | 1.3 | +14.8% | |||||||
3
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Daiichi Sankyo Co. Ltd. published this content on 30 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 July 2021 04:08:04 UTC.
